PPARs,Insulin Resistance and Type 2 Diabetes

King H Aubert RE Herman WH. Global burden of diabetes, 1995–2025 Prevalence, numerical estimates and projections. Diabetes Care 1998; 21:1414–1431.

Zimmet PZ Alberti KGMM. The changing face of macrovascular disease in non-insulin dependent diabetes mellitus: An epidemic in progress. Lancet 1997; 350 (suppl 1):1–4.

Nathan DM Meigs J Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is … or is it? Lancet 1997; 350 (suppl 1):S14–S19.

UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837–853.

Yki-Jarvinen H. Evidence for a primary role of insulin resistance in the pathogenesis of type 2 diabetes. Ann Med 1990; 22:197–200.

Eriksson J Franssila-Kallunki A Ekstrand A Saloranto C Widen E Schalin C Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321:337–343.

Haffner SM Valdez RA Hazuda HP Mitchell BD Morales PA Stern MP. Prospective analysis of the insulin-resistance syndrome (Syndrome X). Diabetes 1992; 41: 715–722.

Reaven GM. Banting Lecture 1988 Role of insulin in human disease. Diabetes 1988; 37:1595–1607.

Haffner SM Miettinen H. Insulin resistance implications for type 2 diabetes mellitus and coronary heart disease. Am J Med 1997; 103:152–162.

American Diabetes Association. Consensus Development Conference on Insulin Resistance. Diabetes Care 1998; 21:310–314.

Howard G O'Leary DH Zaccaro D Haffner S Rewers M Hamman R Insulin sensitivity and atherosclerosis. Circulation 1996; 93:1809–1817.

Lehto S Ronnemaa T Pyorala K Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type 2 diabetes. Diabetologia 2000; 43:148–155.

Schwartz MW Kahn SE. Insulin resistance and obesity. Nature 1999; 402:860–861.

Schoonjans K Auwerx J. Thiazolidinediones: An update. Lancet 2000; 355:1008–1010.

Desvergne B Wahli W. Peroxisome proliferator-activity receptors: Nuclear control of metabolism. Endocrinol Rev 1999; 20:649–688.

Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106:467–472.

Lowell BB. PPARgamma an essential regulator of adipogenesis and modulator of fat cell function. Cell 1999; 99:230–253.

Auwerx J Mangelsdorf D. Atherosclerosis XII. In: Stemme S Olsson AG , editors. Excerpta Medica. International Congress Series 1215. Amsterdam: Elsevier; 2000. pp. 21–39.

Miles PDG Barak Y He W Evans RM Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000; 105:287–292.

Kubota N Terauchi Y Miki H Tamemoto H Yamauchi T Komeda K PPARgamma mediates high fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4:597–609.

Ristow M Muller-Wieland D Pfeiffer A Krone W Kahn CR. Obesity associated with a mutations in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339:953–959.

Barroso I Gurnell M Crowley VEF Agostini M Schwabe JW Soos MA Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880–883.

Tontonoz P Nagy L Alvarez JG Thomazy VA Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidised LDL. Cell 1998; 93:241–252.

Ricote M Huang J Fajas L Welch LA Najib J Witztum JL Auwerx J Palinski W Glass CK. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidised low density lipoprotein. Proc Natl Acad Sci USA 1998; 95:7614–7619.

Marx N Schoenbeck U Lazar MA Lippy P Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibitor gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097–1103.

Saltiel AR Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45:1661–1669.

Ibrahimi A Teboul L Gaillard D Amri EZ Ailhaud G Young P Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in pre-adipose cells. Mol Pharmacol 1994; 46:1070–1076.

Fonseca VA Reynolds T Hemphill D Randolph C Wall J Valiquet TR Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12:181–186.

Horton ES Whitehouse F Ghazzi MN Venable TC Whitcomb RW. Troglitazone in combination with sulphonylurea restores glycaemic control in patients with type 2 diabetes. Diabetes Care 1998; 21:1462–1469.

Buse J Gumbiner B Mathias NP Nelson DM Faja BW Whitcomb RW. Troglitazone use in insulin treated type 2 diabetic patients. Diabetes Care 1998; 21:1455–1461.

Schwartz S Raskin P Fonseca V Graveline J. Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus. N Engl J Med 1998; 338:861–866.

Suter S Nolan J Wallace P Gumbiner B Olefsky JM. Metabolic effects of a new oral hypoglycaemia agent CS-045 in non insulin dependent diabetic subjects. Diabetes Care 1992; 15:193–203.

Sunayama S Watanabe Y Daida H Yamaguchi O. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. Curr Opin Lipidol 2000; 11:397–402.

Tack CJ Smits P Demacker PN Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21:796–799.

Hirano T Yoshino G Kazumi T. Troglitazone and small low density lipoprotein in type 2 diabetes. Ann Int Med 1998; 129:162–163.

Shirai K Itoh Y Sasaki H Totsuka M Murano T Watanabe H Miyashita Y. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in postheparin serum. Diabetes Res Clin Pract 1999; 46:35–41.

Sunayama S Watanabe Y Ohmura H Sawano M Shimada K Mokuno H Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 1999; 146:187–193.

Matsumoto K Miyake S Yano M Ueki Y Tominaga Y. Increase of lipoprotein(a) with troglitazone. Lancet 1997; 350:1748–1749.

Ovalle F Bell DS. Troglitazone's effect on lipoprotein(a) levels. Diabetes Care 1999; 22:859–860.

Ishizuka T Itaya S Wada H Ishizawa M Kimura M Kajita K Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998; 47:1494–1500.

Ebeling P Teppo AM Koistinen HA Viikari J Ronnemaa T Nissen M Troglitazone reduces hyperglycaemia and selectivity acute-phase serum proteins in patients with type 2 diabetes. Diabetologia 1999; 42:1433–1438.

Ogihara T Takugi H Ikegami H Mikami H Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8:316–320.

Imano E Kanda T Nakatani Y Nishida T Arai K Motomura M Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21:2135–2139.

Martin G Schoonjans K Staels B Auwerx J. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998; 137 (suppl 1):S75–S80.

Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47:507–514.

Kobayashi J Nagashima I Hikita M Bujo H Takahashi K Otabe M Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 1999; 47:433–439.

Schoonjans K Peinado-Onsurbe J Lefebvre AM Heyman RA Briggs M Deeb S PPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional message via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15:5336–5348.

Lefebvre AM Peinado-Onsurbe J Leitersdorf I Briggs MR Paterniti JR Fruchart JC Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Atheroscl Thromb Vasc Biol 1997; 17:1756–1764.

Kelly IE Han TS Walsh K Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22:288–293.

Tontonoz P Nagy L. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: Implications for cardiovascular disease. Curr Opin Lipidol 1999; 10:485–490.

Law RE Mechan WP Xi X-P Graf K Wuthrich DA Coats W Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98:1897–1905.

Shiomi M Ito T Tsukada T Tsujita Y Horikoshi H. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin an inhibitor of HMG CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis 1999; 142:345–353.

Minamikawa J Tanaka S Yamamuchi M Inoue D Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83:1818–1820.

Day C. Thiazolidinediones: A new class of antidiabetic drugs. Diabetic Med 1999; 16:179–192.

Scheen AJ Lefebvre PJ. Troglitazone: Antihyperglycaemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22:1568–1577.

Camp HS Li O Wise SC Hong YH Frankowski CL Shen X Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000; 49:539–547.

Krentz AJ Bailey CJ Melander A. Thiazolidinediones for type 2 diabetes. New Agents reduce insulin resistance but need long term clinical trials. Br Med J 2000; 321:252–253.

Freid J Everitt D Boscia J. Rosiglitazone and hepatic failure. Ann Intern Med 2000; 132:164.

Al-Salman J Arjomand H Kemp DG Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 132:121–124.

National Institute for Clinical Excellence. Guidance on rosiglitazone for type 2 diabetes mellitus. Technology appraisal guidance No. 9 London; 2000.

Wolffenbuttel BH Gomis R Squatrito S Jones NP Patwardhan RN. Addition of low-dose rosiglitazone to sulphonlurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17:40–47.

Li AC Brown KK Sibestre MJ Willson TM Palinski W Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106:523–531.

Lawrence J Reckless JPD. Pioglitazone. Int J Clin Pract 2000; 54:614–618.

Rubens HB Robins SJ Collins D Fye CL Anderson JW Elam MB For the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999; 341:410–418.